...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Degenerative Neurological and Neuromuscular Disease >Biomarkers of multiple sclerosis: current findings
【24h】

Biomarkers of multiple sclerosis: current findings

机译：多发性硬化症的生物标志物：最新发现

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is associated with chronic inflammation leading to demyelination and neurodegeneration. With the recent increase in the number of available therapies for MS, optimal treatment will be based on a personalized approach determined by an individual patient’s prognosis and treatment risks. An integral part of such therapeutic decisions will be the use of molecular biomarkers to predict disability progression, monitor ongoing disease activity, and assess treatment response. This review describes current published findings within the past 3 years in biomarker research in MS, specifically highlighting recent advances in the validation of cerebrospinal fluid biomarkers such as neurofilaments (light and heavy chains), chitinases and chitinase 3-like proteins, soluble surface markers of innate immunity, and oligoclonal immunoglobulin M antibodies. Current research in circulating miRNAs as biomarkers of MS is also discussed. Continued validation and testing will be required before MS biomarkers are routinely applied in a clinical setting.
机译：多发性硬化症（MS）是一种影响大脑和脊髓的自身免疫性疾病，与导致脱髓鞘和神经变性的慢性炎症有关。随着最近可用于MS的疗法数量的增加，最佳治疗将基于个体患者的预后和治疗风险确定的个性化方法。此类治疗决策不可或缺的一部分将是使用分子生物标记物来预测残疾进展，监测正在进行的疾病活动并评估治疗反应。这篇综述描述了近三年来在MS的生物标志物研究中最新发表的发现，特别着重强调了在验证脑脊液生物标志物（例如神经丝（轻链和重链），几丁质酶和几丁质酶3样蛋白，可溶性表面标志物）方面的最新进展。先天免疫和寡克隆免疫球蛋白M抗体。还讨论了循环miRNA作为MS生物标志物的当前研究。在临床环境中常规应用MS生物标志物之前，将需要继续进行验证和测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号